Article Details

AI disease modelling startup CytoReason to scale up in US - ISRAEL21c

Retrieved on: 2024-07-18 20:15:08

Tags for this article:

Click the tags to see associated articles and topics

AI disease modelling startup CytoReason to scale up in US - ISRAEL21c. View article details on hiswai:

Summary

Israeli startup CytoReason, focusing on biotech through AI disease modeling, secures $80 million from American brands NVIDIA, Pfizer, Thermo Fisher, and OurCrowd. This investment will expand its US presence and enhance drug development capabilities.

Article found on: www.israel21c.org

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up